On November 10, 2025, the FDA removed the boxed warning — the strongest safety label the agency uses — from all menopausal hormone therapy products, per the FDA's press announcement that day. The same action approved labeling changes intended to describe risks more precisely, and two days later, on November 13, 2025, the agency approved the first generic version of Premarin (conjugated estrogens) in more than 30 years. This site publishes information, not medical advice; decisions about hormone therapy belong with you and your own clinician.
What actually changed on the label?
The boxed warning previously appeared on every estrogen and estrogen-plus-progestin product for menopausal symptoms, and it stated risks of heart disease, breast cancer, and stroke in blanket language. Per the FDA's November 10, 2025 announcement, that warning was judged misleading in its generality, and the agency said labels should describe risk factors that differ by product, dose, route, and a woman's age and time since menopause. The new labeling carries a recommendation, per the FDA, that systemic hormone therapy be started within 10 years of menopause onset or before age 60 for most women who use it.
Why a boxed warning existed at all
The warning dates to 2002–2003, when the Women's Health Initiative — a large randomized trial reported by NIH researchers in JAMA — linked combined estrogen-progestin therapy to higher risks of breast cancer, stroke, and blood clots. Those findings were real, but later analyses, including the 2017 JAMA follow-up led by JoAnn Manson, found that 5 to 7 years of hormone therapy were not associated with higher long-term all-cause mortality. Risk, in other words, depended heavily on age, timing, and formulation — nuance a one-size boxed warning could not carry.
Related stories: WIC is funded through September 2026, with produce benefits intact · Women's health venture funding fell to $1.58 billion in 2025.
What the generic approval changes
Premarin, first approved in 1942, had been the only conjugated estrogens product on the US market since 1991, when the FDA withdrew approval of earlier generic versions over efficacy concerns, per the agency's November 13, 2025 announcement. A generic conjugated estrogens tablet introduces price competition into a category that had none for over three decades. The FDA did not announce a launch date or price; availability depends on the manufacturer's rollout.
What it means if you use or stopped hormone therapy
Nothing about the science changed in November 2025 — the communication did. Symptoms such as hot flashes and sleep disruption remain treatable, and options now include hormonal and non-hormonal drugs approved in recent years. If you stopped therapy because of the warning, or avoided asking about it, the label change may make the conversation with your clinician more balanced. The decision still turns on your own history: clotting risk, breast cancer risk, blood pressure, and how recently menopause began.
The context most coverage skipped
Former safety monitors from the Women's Health Initiative publicly objected to the change, warning — as reported by NPR on November 12, 2025 — that softening the label could erode appropriate caution. The dispute is less about whether hormone therapy helps symptoms and more about who bears the burden of residual uncertainty: the boxed warning put it on the drug; the FDA has now moved it back to the prescribing conversation. Watch how malpractice standards, pharmacy counseling protocols, and insurers' prior-authorization rules absorb the new labels through 2026 — that is where access will actually shift.